NSAIDS inhibit the IL-1β-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2

[1]  C. D. DE GROOT,et al.  Establishment of human adult astrocyte cultures derived from postmortem multiple sclerosis and control brain and spinal cord regions: immunophenotypical and functional characterization , 1997, Journal of neuroscience research.

[2]  H. Fraser,et al.  Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-1 in the CNS during the incubation period of murine scrapie correlates with progressive PrP accumulations , 1997, Brain Research.

[3]  R. Mrak,et al.  Glial‐Neuronal Interactions in Alzheimer Disease: Progressive Association of IL‐1α+ Microglia and S100β+ Astrocytes with Neurofibrillary Tangle Stages , 1997, Journal of neuropathology and experimental neurology.

[4]  W F Stewart,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.

[5]  H. Prast,et al.  Modulation of histamine release in the hypothalamus by nitric oxide , 1997, Inflammation Research.

[6]  M. Hüll,et al.  Prostaglandin E2 Induces Interleukin‐6 Synthesis in Human Astrocytoma Cells , 1997, Journal of neurochemistry.

[7]  J. Frölich.  A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. , 1997, Trends in pharmacological sciences.

[8]  E. Major,et al.  Recombinant human interleukin 1β induces production of prostaglandins in primary human fetal astrocytes and immortalized human fetal astrocyte cultures , 1996, Journal of Neuroimmunology.

[9]  Julia W. Chang,et al.  Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease , 1996, Neurobiology of Aging.

[10]  M. Hüll,et al.  Interleukin-6-associated inflammatory processes in Alzheimer's disease: New therapeutic options , 1996, Neurobiology of Aging.

[11]  S. Stein,et al.  Prostaglandin E2 potentiates interleukin-1 beta induced interleukin-6 production by human gingival fibroblasts. , 1996, Journal of clinical periodontology.

[12]  P. Eikelenboom,et al.  Do Nonsteroidal Anti-Inflammatory Drugs Have a Protective Effect Against Dementia? , 1996, Drugs & aging.

[13]  P. Aisen,et al.  IL-1 and anti-inflammatory drugs modulate A β cytotoxicity in PC12 cells , 1996, Brain Research.

[14]  R. Veerhuis,et al.  Amyloid β Protein Primes Cultured Rat Microglial Cells for an Enhanced Phorbol 12‐Myristate 13‐Acetate‐Induced Respiratory Burst Activity , 1996, Journal of neurochemistry.

[15]  Julia W. Chang,et al.  Interleukin‐1β Induces Prostaglandin G/H Synthase‐2 (Cyclooxygenase‐2) in Primary Murine Astrocyte Cultures , 1996, Journal of neurochemistry.

[16]  E. Shacter,et al.  Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Brattsand,et al.  Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. , 1996, Alimentary pharmacology & therapeutics.

[18]  J. Breitner.  The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. , 1996, Annual review of medicine.

[19]  R. Rydel,et al.  Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Baldwin,et al.  Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.

[21]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[22]  A. Hofman,et al.  Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? , 1995, Neurology.

[23]  P. Dash,et al.  Enhanced processing of APP induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid. , 1995, Biochemical and biophysical research communications.

[24]  G. Forloni,et al.  Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures , 1995, Neuroscience Letters.

[25]  D. Walker,et al.  Complement and cytokine gene expression in cultured microglia derived from postmortem human brains , 1995, Journal of neuroscience research.

[26]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[27]  K. Seibert,et al.  Mediation of inflammation by cyclooxygenase-2. , 1995, Agents and actions. Supplements.

[28]  J. Breitner.  New epidemiologic strategies in Alzheimer's disease may provide clues to prevention and cause , 1994, Neurobiology of Aging.

[29]  P. Eikelenboom,et al.  Inflammatory mechanisms in Alzheimer's disease. , 1994, Trends in pharmacological sciences.

[30]  K. Davis,et al.  Inflammatory mechanisms in Alzheimer's disease: implications for therapy. , 1994, The American journal of psychiatry.

[31]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[32]  A. Ray,et al.  Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[36]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Carè,et al.  Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha. , 1992, Journal of immunology.

[38]  P. Mcgeer,et al.  Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease , 1992, Neurochemistry International.

[39]  J. Vilček,et al.  Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-κ B-like nuclear protein , 1992, Journal of Neuroimmunology.

[40]  P. Eikelenboom,et al.  Activated microglia and cerebral amyloid deposits in Alzheimer's disease. , 1992, Research in immunology.

[41]  W. Kamphorst,et al.  Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer's disease. , 1992, Research in immunology.

[42]  S. J. Lee,et al.  Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis. , 1992, The Journal of pharmacology and experimental therapeutics.

[43]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[44]  U. Schreiter-Gasser,et al.  Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices , 1991, FEBS letters.

[45]  W. Fiers,et al.  Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? , 1991, Immunology today.

[46]  F. Clerck,et al.  Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[47]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[48]  P. Mcgeer,et al.  Anti-inflammatory drugs and Alzheimer disease , 1990, The Lancet.

[49]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Scott,et al.  Rheumatold Arthritis and Senile Dementia of the Alzhelmer's Type , 1989 .

[51]  T. Nishida,et al.  Dexamethasone regulation of the expression of cytokine mRNAs induced by interleukin‐1 in the astrocytoma cell line U373MG , 1989, FEBS letters.

[52]  J. Krebs,et al.  Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[54]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.